Eculizumab Drug Aliquot | Anti-C5 complement protein | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Eculizumab are now available as research consumables.

Eculizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Eculizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Soliris® / Eculizumab Reference Product

Drug nameSoliris®
API typeEculizumab is a humanised monoclonal (IgG2/4κ) antibody produced in NS0 cell line by recombinant DNA
Pharmacotherapeutic group
Selective immunosuppressants
ATC code
Target of antibody
C5 complement protein
General functionEculizumab is indicated in adults and children for the treatment of Paroxysmal nocturnal haemoglobinuria (PNH) and Atypical haemolytic uremic syndrome (aHUS).
Eculizumab is also indicated in adults for the treatment of Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive, Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Eculizumab is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and
preventing the generation of the terminal complement complex C5b-9. Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.
In PNH patients, uncontrolled terminal complement activation and the resulting complement-mediated intravascular haemolysis is blocked with Eculizumab treatment.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)No interaction studies have been performed. Based on the potential inhibitory effect of eculizumab on
complement-dependent cytotoxicity of rituximab, eculizumab may reduce the expected pharmacodynamic effects of rituximab.
Original license holder
Alexion Europe SAS
Marketing authorisation numbers
Marketing authorisation holder
Alexion Europe SAS
103-105 rue Anatole France
92300 Levallois-Perret
Name of the manufacturer of the biological active substance
Lonza Biologics Tuas Pte Ltd.
35 Tuas South Avenue 6
Singapore 637377

Lonza Biologics Porriño, S.L.
C/ La Relba, s/n.
Pontevedra 36400

Alexion Pharma International Operations Unlimited Company
College Business and Technology Park
Blanchardstown, Dublin 15
Name and address of the manufacturer(s) responsible for batch releaseAlmac Pharma Services
22 Seagoe Industrial Estate
Craigavon BT63 5QD
United Kingdom

Patheon Italia S.p.A
Viale G. B. Stucchi, 110
20900 Monza (MB)

Alexion Pharma International Operations Unlimited Company
College Business and Technology Park
Dublin 15
Max shelf life
30 months
Storage conditions
2°C – 8°C
List of excipients
Sodium phosphate, monobasic
Sodium phosphate, dibasic
Sodium chloride
Polysorbate 80
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.